KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) EPS (Weighted Average and Diluted) (2016 - 2025)

Boston Scientific (BSX) has disclosed EPS (Weighted Average and Diluted) for 17 consecutive years, with $0.45 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 18.42% to $0.45 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.94 through Dec 2025, up 55.2% year-over-year, with the annual reading at $1.94 for FY2025, 55.2% up from the prior year.
  • EPS (Weighted Average and Diluted) hit $0.45 in Q4 2025 for Boston Scientific, down from $0.51 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.53 in Q2 2025 to a low of $0.06 in Q4 2021.
  • Historically, EPS (Weighted Average and Diluted) has averaged $0.27 across 5 years, with a median of $0.26 in 2021.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 2200.0% in 2021 and later plummeted 69.57% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.06 in 2021, then skyrocketed by 50.0% to $0.09 in 2022, then soared by 277.78% to $0.34 in 2023, then grew by 11.76% to $0.38 in 2024, then grew by 18.42% to $0.45 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for BSX at $0.45 in Q4 2025, $0.51 in Q3 2025, and $0.53 in Q2 2025.